secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059104
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana Q1 net loss $19.3M ($0.16/shr); XMT-1660 Phase 1 ongoing, XMT-2056 resumed
--------------------------------------------------------------------------------

- Net loss of $19.3M ($0.16/shr) vs $56.2M loss ($0.52) in Q1 2023; collaboration revenue $9.2M (up from $7.8M).
- Cash, equivalents and securities $183.1M; expects runway into 2026.
- XMT-1660 Phase 1 dose escalation continues; MTD not yet reached; initial data and expansion expected H2 2024.
- XMT-2056 Phase 1 resumed enrollment after clinical hold lifted; dose escalation planned in 2024.
- R&D expenses fell sharply to $18.7M from $47.3M driven by UpRi discontinuation and restructuring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/0001104659-24-059104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465924059104/tm2413939d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer